Black individuals are more than twice as likely to die from prostate cancer than non-Hispanic white individuals and are more likely to be diagnosed at later, more advanced stages when the disease is harder to treat. These disparities are not acceptable.
The DIVERSE Trials Act would remove barriers that keep certain racial and ethnic groups, including Black cancer patients, from being represented in clinical trials
